Antibiotic lung penetration study launches in china
NCT ID NCT07124468
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial in 16 healthy adults in China measures how much of the intravenous antibiotic Meropenem-Pralubactam gets into lung fluids and cells. Researchers aim to find the drug's concentration in plasma, epithelial lining fluid, and alveolar macrophages after four doses. The study does not treat any infection but provides key data for future dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Meropenem-Pralubactam (an antibiotic combination given intravenously)
- What this could lead to
- If successful, this study could help doctors understand the right dose of this antibiotic to treat lung infections.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only measures drug levels, not whether the drug works against infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple shot under the skin replace an IV for a key antibiotic in the elderly?
- Experimental malaria vaccine aims to block parasite growth
- Rare disease drug shows promise in reducing infections
- New rapid test for infection and inflammation put to the test
- Fast new swab test could speed up vaginitis diagnosis
- Scientists crack the code of antibiotic-friendly superbug